Skip to the page

Data / Drug companies / Virtu Pharmako (Zhejiang) Co., Ltd.

Virtu Pharmako (Zhejiang) Co., Ltd.: 24 products in the FDA NDC directory, labeler code 85827

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Virtu Pharmako (Zhejiang) Co., Ltd. (labeler code 85827) lists 24 products in the FDA National Drug Code Directory. By type: 24 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on September 13, 2026.

The request: Watch Virtu Pharmako (Zhejiang) Co., Ltd. (FDA labeler code 85827): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
85827
Products in commercial distribution
24
Packages
24
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
24
Earliest marketing start
December 20, 2025
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Bulk ingredients24100%

Products by type

TypeProductsShare
Bulk ingredients24100%

Dosage forms

Dosage formProductsShare
Powder24100%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Insulin glargine85827-204PowderBulk ingredientsSeptember 13, 2026
Insulin glargine85827-204PowderBulk ingredientsSeptember 13, 2026
Insulin glargine85827-204PowderBulk ingredientsSeptember 13, 2026
Insulin glargine85827-204PowderBulk ingredientsSeptember 13, 2026
Insulin glargine85827-204PowderBulk ingredientsSeptember 13, 2026
Insulin aspart85827-203PowderBulk ingredientsSeptember 13, 2026
Insulin aspart85827-203PowderBulk ingredientsSeptember 13, 2026
Insulin aspart85827-203PowderBulk ingredientsSeptember 13, 2026
Insulin aspart85827-203PowderBulk ingredientsSeptember 13, 2026
Insulin aspart85827-203PowderBulk ingredientsSeptember 13, 2026
Insulin human85827-202PowderBulk ingredientsJuly 30, 2026
Insulin human85827-202PowderBulk ingredientsJuly 30, 2026
Insulin human85827-202PowderBulk ingredientsJuly 30, 2026
Insulin human85827-202PowderBulk ingredientsJuly 30, 2026
Insulin human85827-202PowderBulk ingredientsJuly 30, 2026
Insulin detemir85827-201PowderBulk ingredientsJune 24, 2026
Insulin detemir85827-201PowderBulk ingredientsJune 24, 2026
Insulin detemir85827-201PowderBulk ingredientsJune 24, 2026
Semaglutide85827-302PowderBulk ingredientsJanuary 1, 2026
Semaglutide85827-301PowderBulk ingredientsJanuary 1, 2026
Semaglutide85827-302PowderBulk ingredientsDecember 31, 2025
Semaglutide85827-301PowderBulk ingredientsDecember 31, 2025
Semaglutide85827-301PowderBulk ingredientsDecember 24, 2025
Semaglutide85827-302PowderBulk ingredientsDecember 20, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.